From the Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran (Drs. Togha and Ashrafian); and Department of Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran (Dr. Tajik).
Open-Label Trial of Cinnarizine in Migraine Prophylaxis
Article first published online: 21 MAR 2006
Headache: The Journal of Head and Face Pain
Volume 46, Issue 3, pages 498–502, March 2006
How to Cite
Togha, M., Ashrafian, H. and Tajik, P. (2006), Open-Label Trial of Cinnarizine in Migraine Prophylaxis. Headache: The Journal of Head and Face Pain, 46: 498–502. doi: 10.1111/j.1526-4610.2006.00381.x
- Issue published online: 21 MAR 2006
- Article first published online: 21 MAR 2006
- Accepted for publication June 1, 2005.
Objective.—To assess the effectiveness and safety of cinnarizine as a migraine-preventive therapy.
Methods.—Sixty patients with more than 2 migraine headache attacks during a 4-week baseline entered the study and received a 25-mg tablet cinnarizine twice daily for the first 3 days and then 3 times daily. They were assessed on weeks 2, 6, 10, and 14. Reduction from baseline in 4-week migraine headache rate was the primary efficacy variable. Reduction in migraine attacks duration and severity was also evaluated.
Results.—The mean reduction in 4-week migraine headache rate was 4.6 ± 2.2 from the baseline of 6.2 ± 2.2 after 14 weeks of treatment, which was statistically significant (P < 0.001). Percent reduction in 4-week migraine frequency was 35% after 2 weeks, 74% after 6 weeks, 74% after 10 weeks, and 75% after 14 weeks of treatment. Significant reduction in attack duration (P < 0.001) and severity (P < 0.001) was also noted. No serious adverse events were observed in this series of patient.
Conclusion.—Cinnarizine is an efficacious and well-tolerated prophylactic antimigraine medication, which has early onset effectiveness.